Bayer’s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes

·         Finerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care

·         Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events